Search

Displaying results 4011 - 4020 of 10000 in total
  1. Drug

    2,5-Dimethoxy-4-ethylthioamphetamine

    go.drugbank.com/drugs/DB13940
    Experimental

    2,5-Dimethoxy-4-ethylthioamphetamine (ALEPH-2) is a phenylisopropylamine derivative with alleged anxiolytic and hallucinogenic properties.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  2. Drug

    Cymarin

    go.drugbank.com/drugs/DB13240
    Experimental

    Categories: Compounds used in a research, industrial, or household setting
  3. Drug

    Pegsunercept

    go.drugbank.com/drugs/DB06611
    Investigational

    Pegsunercept is used for treating rheumatoid arthritis. Phase II clinical trials were completed in January 2010.

    Categories: Compounds used in a research, industrial, or household setting
  4. Drug

    Bucillamine

    go.drugbank.com/drugs/DB12160
    Investigational

    Bucillamine has been used in trials studying the treatment and prevention of Gout and Rheumatoid Arthritis.

    Categories: Compounds used in a research, industrial, or household setting
  5. Drug

    Maxacalcitol

    go.drugbank.com/drugs/DB06272
    Investigational

    Categories: Compounds used in a research, industrial, or household setting
  6. Drug

    N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline

    go.drugbank.com/drugs/DB02855
    Experimental

    Categories: Compounds used in a research, industrial, or household setting
  7. Drug

    Chelerythrine

    go.drugbank.com/drugs/DB17024
    Experimental

    A benzophenanthridine alkaloid evaluated as a kinase-inhibitor.

    Categories: Heterocyclic Compounds with 4 or More Rings
  8. Drug

    Alphaprodine

    go.drugbank.com/drugs/DB13160
    ExperimentalIllicit

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  9. Drug

    Nalfurafine

    go.drugbank.com/drugs/DB13471
    Investigational

    Categories: Heterocyclic Compounds with 4 or More Rings
  10. Drug

    Eculizumab

    go.drugbank.com/drugs/DB01257
    ApprovedInvestigational

    [L6919] In Q1 2023, the EMA's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion of two formulations of eculizumab indicated for the treatment of paroxysmal nocturnal hemoglobinuria … [L6919,A2245] Binding to this protein prevents the activation of a complement terminal complex, which is used to treat a number of autoimmune conditions.

    Products: SOLIRIS 300 MG/30 ML KONSANTRE İNFÜZYON ÇÖZELTİSİ, Bekemv 300 mg/30 mL İnfüzyonluk Çözelti Hazırlamak İçin Konsantre, 1 ADET